Oxford Biomedica Receives European Patent for TroVax

Oxford BioMedica, the leading gene therapy company, announced that the European Patent Office has granted a key patent (No. EP1036091), that provides broad protection for Oxford BioMedica's lead product, TroVax. This is one of several granted and pending patents that protect the company's ownership of the 5T4 tumour antigen. The granted patent covers immunotherapy products directed against 5T4 and includes specific claims to the use of viral delivery systems in 5T4-targeted vaccines.

Bioportfolio (http://www.bioportfolio.com/news/oxford_biomedica_49.htm)